Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This article reviews the role and clinical applications of 1,25-dihydroxyvitamin D3 and parathyroid hormone-related peptide in dermatology, with a focus on psoriasis treatment, and reports no new experimental findings.

This study found that the protein CCN2 in dermal papilla cells is a physiologically relevant suppressor of hair follicle formation by destabilizing β-catenin, which may help maintain stem cell quiescence.

This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

This article reviews endocrine therapies for androgen excess disorders, emphasizing spironolactone, estrogen, and dexamethasone as effective treatments; it reports no new clinical results.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

This study found that activating CB1 receptor signaling in human hair follicles increased stem cell proliferation while reducing differentiated cell survival, suggesting CB1's role as a survival stimulus for epithelial stem cells.

This study describes the development of a monoclonal antibody, 005-C04, which blocks PRLR-mediated signaling, suggesting its potential for furthering understanding of PRLR's role in health and disease.

This review discusses various treatment options for chronic central serous chorioretinopathy, evaluating studies conducted since 2000, but reports no new clinical results.

In this study, researchers identified gremilin-2 as a highly specific gene to the dermal sheath cup, suggesting it plays a key role in maintaining its properties.

This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

This study found that polymeric micelle nanocarriers delivered pharmacologically relevant amounts of spironolactone to the epidermis and upper dermis, with higher delivery to pilosebaceous units, suggesting potential for treating glucocorticoid-induced impaired wound healing and pilosebaceous androgen-related skin diseases.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.

This review discusses the regulation of hair growth, causes of excessive androgen secretion, and current safe solutions for hyperandrogenism manifestations in women but reports no new clinical results.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

This review summarizes recent therapeutic advancements in treating various forms of alopecia, including new applications of oral minoxidil, dutasteride, finasteride, Janus kinase inhibitors, and novel hair transplant techniques, without presenting original research results.

This study found that topical MR blockers alongside glucocorticoids may limit glucocorticoid-induced skin atrophy, suggesting MR's significant role in skin-related endocrinology.

This study found that male patients with androgenetic alopecia had significantly higher aldosterone levels and blood pressure compared to controls, suggesting a possible link between AGA and hypertension.

This review discusses hormonal manipulation for conditions like prostatic disorders and skin issues and highlights promising treatments like casodex and finasteride, but it reports no new clinical results.

This case report documents two postmenopausal women with frontal fibrosing alopecia whose hair loss stabilized after treatment with topical corticosteroids, one also using minoxidil.

TLR7-based compounds may help manage chemotherapy-induced hair loss.

This article reviews androgenic disorders in women, such as PCOS, highlighting how understanding these conditions could improve their management, but it presents no new clinical findings.

This article outlines a practical method for diagnosing and managing feline symmetrical alopecia but presents no new empirical findings.

This study found that androgen impacted glucocorticoid signaling in the mouse brain only in the prefrontal cortex and substantia nigra, suggesting limited interaction between these hormones at high corticosterone levels.

This review discusses the risk of central nervous side effects, such as dementia and depression, from drugs used to treat lower urinary symptoms related to benign prostatic hyperplasia, and highlights inconsistent evidence across different medications.

This article discusses the various roles of steroids in vertebrate organ systems and notes several glucocorticoids that were among the Top 200 Drugs by sales in the 2010s, but it reports no new clinical findings.